Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Taisho Postpones Some R&D Spending Due to Development Delays
November 22, 2004
- PhRMA Publishes Japanese Version of Principles for Conducting Clinical Trials
November 15, 2004
- OTC NEWS IN BRIEF
November 15, 2004
- Mediceo HD Forms Capital Tie-up with Chain Management
November 15, 2004
- MEDICAL DEVICE NEWS IN BRIEF
November 15, 2004
- Tokyo CRO Establishes Its Subsidiary Tokyo CSO
November 15, 2004
- Yamanouchi: Net Profits Down 30.9% due to One-time Costs Related to Merger
November 15, 2004
- BUSINESS NEWS IN BRIEF
November 15, 2004
- Fujisawa: Sales Up 4.1% to \204.5 Bil.
November 15, 2004
- Micardis Slows Progression of Nephropathy in Type 2 Diabetic Patients: Prof. Barnett
November 15, 2004
- WEBSITE NEWS
November 15, 2004
- Semiannual Business Results
November 15, 2004
- Iryo Proverbs Reveal Japanese Spirit (24)
November 15, 2004
- Generic, Switch-OTC PPIs Threaten Sales of Pariet in US: Eisai
November 15, 2004
- BULLETIN
November 15, 2004
- Business Outlook Improving for MPC: Mr Komine
November 15, 2004
- Free-price System for Innovative Drugs Is One Option: Dr Fujii
November 15, 2004
- Shionogi: Profits Up Sharply Despite Decline in Sales
November 15, 2004
- Korosho Withdraws Recommendations for Antibiotics Skin Tests: Safety Info
November 15, 2004
- Santen: Sales Down 2.3% to \45.0 Bil.
November 15, 2004
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…